BRPI0513777A - composto ou um sal do mesmo, composição farmacêutica, e, uso de um composto ou de um sal do mesmo - Google Patents
composto ou um sal do mesmo, composição farmacêutica, e, uso de um composto ou de um sal do mesmoInfo
- Publication number
- BRPI0513777A BRPI0513777A BRPI0513777-2A BRPI0513777A BRPI0513777A BR PI0513777 A BRPI0513777 A BR PI0513777A BR PI0513777 A BRPI0513777 A BR PI0513777A BR PI0513777 A BRPI0513777 A BR PI0513777A
- Authority
- BR
- Brazil
- Prior art keywords
- nitrogen
- formula
- salt
- compound
- ring
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000002393 azetidinyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 125000003386 piperidinyl group Chemical group 0.000 abstract 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 229940115480 Histamine H3 receptor antagonist Drugs 0.000 abstract 1
- 229940122931 Histamine H3 receptor inverse agonist Drugs 0.000 abstract 1
- 102000004384 Histamine H3 receptors Human genes 0.000 abstract 1
- 108090000981 Histamine H3 receptors Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- -1 aryl oxazole compounds Chemical class 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000003631 narcolepsy Diseases 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
COMPOSTO OU UM SAL DO MESMO, COMPOSIçãO FARMACêUTICA, E, USO DE UM COMPOSTO OU DE UM SAL DO MESMO A presente invenção revela compostos inéditos de aril oxazol de Fórmula I (I), ou seus sais farmaceuticamente aceitáveis, que apresentam atividade antagonista ou agonista inversa de receptor de histamina-H3, e também métodos para preparar e usar referidos compostos. Em outra concretização, a invenção revela composições farmacêuticas compreendendo compostos de Fórmula I, e também métodos de usar estas composições para tratar obesidade, deficiências cognitivas, narcolepsia e outras doenças relacionadas com receptor de histamina H3. Fórmula I (I) ou um sal farmaceuticamente aceitável da mesma, em que: m é, independentemente, em cada ocorrência, 1, 2 ou 3, Z representa independentemente carbono (substituído com hidrogênio ou pelos substituintes opcionais aqui indicados) ou nitrogênio, desde que, quando Z for nitrogênio, então R6 não seja ligado a Z; R1 e R2 são independentemente -(Cl-C7) alquila (opcionalmente substituído com de um a três halogênios), ou R1 e R2 e o nitrogênio a que estão ligados formam um anel azetidinila, um anel pirrolidinila, ou um anel piperidinila, sendo que, adicionalmente, um anel pirrolidinila ou anel piperidinila, sendo que, adicionalmente, o anel azetidinila, pirrolidinila, ou piperidinila assim formado pode ser opcionalmente substituído de uma a três vezes com R5; R6 é, independentemente, em cada ocorrência, -H, -halogênio, ou -CH~ 3~.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59119104P | 2004-07-26 | 2004-07-26 | |
| PCT/US2005/024883 WO2006019833A1 (en) | 2004-07-26 | 2005-07-14 | Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0513777A true BRPI0513777A (pt) | 2008-05-13 |
Family
ID=35134220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0513777-2A BRPI0513777A (pt) | 2004-07-26 | 2005-07-14 | composto ou um sal do mesmo, composição farmacêutica, e, uso de um composto ou de um sal do mesmo |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7666871B2 (pt) |
| EP (1) | EP1786790B1 (pt) |
| JP (1) | JP4982367B2 (pt) |
| CN (1) | CN1989115B (pt) |
| AT (1) | ATE432926T1 (pt) |
| AU (1) | AU2005275183B2 (pt) |
| BR (1) | BRPI0513777A (pt) |
| CA (1) | CA2575081C (pt) |
| CY (1) | CY1109493T1 (pt) |
| DE (1) | DE602005014786D1 (pt) |
| DK (1) | DK1786790T3 (pt) |
| ES (1) | ES2325865T3 (pt) |
| MX (1) | MX2007001029A (pt) |
| PL (1) | PL1786790T3 (pt) |
| PT (1) | PT1786790E (pt) |
| SI (1) | SI1786790T1 (pt) |
| WO (1) | WO2006019833A1 (pt) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8008301B2 (en) * | 2004-04-01 | 2011-08-30 | Eli Lilly And Company | Histamine H3 receptor agents, preparation and therapeutic uses |
| WO2006089076A2 (en) | 2005-02-18 | 2006-08-24 | Neurogen Corporation | Thiazole amides, imidazole amides and related analogues |
| JP2008534542A (ja) | 2005-03-31 | 2008-08-28 | ユセベ ファルマ ソシエテ アノニム | オキサゾール部分又はチアゾール部分を含む化合物、それらの製造方法及びそれらの使用 |
| RU2418793C2 (ru) | 2005-11-15 | 2011-05-20 | Оцука Фармасьютикал Ко., Лтд. | Соединение оксазола и фармацевтическая композиция |
| AU2007227681A1 (en) | 2006-03-15 | 2007-09-27 | Wyeth | N-substituted-azacyclylamines as histamine-3 antagonists |
| WO2007136668A2 (en) | 2006-05-19 | 2007-11-29 | Wyeth | N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists |
| EP2024327A1 (de) * | 2006-05-19 | 2009-02-18 | Basf Se | Benzoylsubstituierte alanine |
| US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| PE20081152A1 (es) | 2006-10-06 | 2008-08-10 | Wyeth Corp | Azaciclilaminas n-sustituidas como antagonistas de histamina-3 |
| US7803825B2 (en) | 2007-07-16 | 2010-09-28 | Wyeth Llc | Aminoalkylazole derivatives as histamine-3 antagonists |
| WO2009126782A1 (en) * | 2008-04-11 | 2009-10-15 | High Point Pharmaceuticals, Llc | Histamine h3 receptor ligands |
| US8383829B2 (en) * | 2008-04-15 | 2013-02-26 | Konica Minolta Holdings, Inc. | Electrochromic compound, electrode, and display element |
| SA110310332B1 (ar) * | 2009-05-01 | 2013-12-10 | Astrazeneca Ab | مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل ) |
| JP5827683B2 (ja) | 2010-07-06 | 2015-12-02 | アストラゼネカ アクチボラグ | 療法薬９７６ |
| UY34194A (es) | 2011-07-15 | 2013-02-28 | Astrazeneca Ab | ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad? |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| BR112015017331B1 (pt) | 2013-01-23 | 2022-01-11 | Astrazeneca Ab | Compostos de formula i, forma cristalina, uso dos compostos, combinação e composição |
| WO2016097071A1 (en) * | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | Estrogen receptor modulators and uses thereof |
| MA41562B1 (fr) | 2015-06-03 | 2019-05-31 | Bristol Myers Squibb Co | Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires |
| HRP20211864T1 (hr) | 2015-07-06 | 2022-03-04 | Alkermes, Inc. | Inhibitori hetero-halo histonske deacetilaze |
| US10421756B2 (en) | 2015-07-06 | 2019-09-24 | Rodin Therapeutics, Inc. | Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase |
| BR112019014235A2 (pt) | 2017-01-11 | 2020-03-17 | Rodin Therapeutics, Inc. | Inibidores bicíclicos de histona desacetilase |
| AU2018313094A1 (en) | 2017-08-07 | 2020-02-20 | Rodin Therapeutics, Inc. | Bicyclic inhibitors of histone deacetylase |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3819037A1 (de) * | 1988-06-04 | 1989-12-14 | Hoechst Ag | 2,4-disubstituierte oxazol-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als therapiemittel gegen krankheiten, die durch rhinoviren verursacht werden |
| KR100196356B1 (ko) * | 1993-09-28 | 1999-06-15 | 오스카 아끼히꼬 | 당뇨병 치료제 |
| AU3957600A (en) | 1999-04-26 | 2000-11-10 | Boehringer Ingelheim International Gmbh | Piperidyl-imidazole derivatives, their preparations and therapeutic uses |
| JP2004532834A (ja) | 2001-03-23 | 2004-10-28 | イーライ・リリー・アンド・カンパニー | ヒスタミンｈ３受容体アンタゴニストである非イミダゾール系アリールアルキルアミン化合物、その製造および治療的使用 |
| EP1474419B1 (en) | 2002-02-01 | 2007-09-05 | Novo Nordisk A/S | Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes |
| US7332508B2 (en) | 2002-12-18 | 2008-02-19 | Novo Nordisk A/S | Substituted homopiperidine, piperidine or pyrrolidine derivatives |
| US7259262B2 (en) * | 2003-10-24 | 2007-08-21 | Hoffmann-La Roche Inc. | Arylazole derivatives, their manufacture and use as pharmaceutical agents |
-
2005
- 2005-07-14 DK DK05773290T patent/DK1786790T3/da active
- 2005-07-14 CN CN200580024874XA patent/CN1989115B/zh not_active Expired - Fee Related
- 2005-07-14 CA CA2575081A patent/CA2575081C/en not_active Expired - Fee Related
- 2005-07-14 JP JP2007523605A patent/JP4982367B2/ja not_active Expired - Fee Related
- 2005-07-14 AT AT05773290T patent/ATE432926T1/de active
- 2005-07-14 PL PL05773290T patent/PL1786790T3/pl unknown
- 2005-07-14 BR BRPI0513777-2A patent/BRPI0513777A/pt not_active IP Right Cessation
- 2005-07-14 US US11/572,283 patent/US7666871B2/en not_active Expired - Fee Related
- 2005-07-14 ES ES05773290T patent/ES2325865T3/es not_active Expired - Lifetime
- 2005-07-14 MX MX2007001029A patent/MX2007001029A/es active IP Right Grant
- 2005-07-14 PT PT05773290T patent/PT1786790E/pt unknown
- 2005-07-14 EP EP05773290A patent/EP1786790B1/en not_active Expired - Lifetime
- 2005-07-14 AU AU2005275183A patent/AU2005275183B2/en not_active Ceased
- 2005-07-14 WO PCT/US2005/024883 patent/WO2006019833A1/en active Application Filing
- 2005-07-14 DE DE602005014786T patent/DE602005014786D1/de not_active Expired - Lifetime
- 2005-07-14 SI SI200530741T patent/SI1786790T1/sl unknown
-
2009
- 2009-08-06 CY CY20091100831T patent/CY1109493T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007001029A (es) | 2007-04-12 |
| US20070197604A1 (en) | 2007-08-23 |
| US7666871B2 (en) | 2010-02-23 |
| JP2008507579A (ja) | 2008-03-13 |
| CY1109493T1 (el) | 2014-08-13 |
| DK1786790T3 (da) | 2009-07-20 |
| CN1989115B (zh) | 2012-03-21 |
| CA2575081C (en) | 2013-05-07 |
| JP4982367B2 (ja) | 2012-07-25 |
| AU2005275183A1 (en) | 2006-02-23 |
| EP1786790B1 (en) | 2009-06-03 |
| ES2325865T3 (es) | 2009-09-22 |
| DE602005014786D1 (de) | 2009-07-16 |
| SI1786790T1 (sl) | 2009-10-31 |
| WO2006019833A1 (en) | 2006-02-23 |
| CA2575081A1 (en) | 2006-02-23 |
| EP1786790A1 (en) | 2007-05-23 |
| CN1989115A (zh) | 2007-06-27 |
| PL1786790T3 (pl) | 2009-10-30 |
| AU2005275183B2 (en) | 2011-03-17 |
| PT1786790E (pt) | 2009-08-18 |
| ATE432926T1 (de) | 2009-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0513777A (pt) | composto ou um sal do mesmo, composição farmacêutica, e, uso de um composto ou de um sal do mesmo | |
| NZ588121A (en) | Novel estrogen receptor ligands | |
| BRPI0608732A2 (pt) | composto ou um sal, hidrato, solvato, complexo ou pró-droga farmaceuticamente aceitável do mesmo, sal de um composto, processo para a preparação de um composto, uso de um composto, composição farmacêutica, e, produto | |
| TWI262917B (en) | 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same | |
| TW200716528A (en) | Cyclopropanecarboxamide derivatives | |
| TW200637550A (en) | Thiazole-4-carboxamide derivatives as mGluR5 antagonists | |
| EA201101398A1 (ru) | Замещенные пиперидины в качестве антагонистов ccr3 | |
| NO20064579L (no) | Bifenylforbindelser anvendelige som muskariniske receptorantagonister | |
| ATE457988T1 (de) | A2a-adenosin-rezeptor-antagonisten | |
| EA200970705A1 (ru) | Новые фармацевтические композиции | |
| ATE325796T1 (de) | Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente | |
| MXPA05007115A (es) | Nuevos agonistas inversos del receptor cb 1. | |
| GB0701366D0 (en) | Novel pharmaceutical compositions | |
| BRPI0512058A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto | |
| AR046085A1 (es) | Agonistas etilamino amino sustituidos del receptor beta 2 adrenergico | |
| MY139612A (en) | Benzoxazine derivatives as 5-th6 modulators and uses thereof | |
| CY1109694T1 (el) | Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης | |
| MX2007005709A (es) | Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida sustituidos. | |
| ES2197003A1 (es) | Nuevos compuestos antagonistas de integrinas alfa. | |
| BRPI0415109A (pt) | compostos de 1-[2-(4-hidroxifenil)-2-hidroxietil]-piperidin-4-ol como antagonistas de receptor de nmda | |
| DE602005007064D1 (de) | Chromanderivate und ihre verwendung als liganden des 5-ht-rezeptors | |
| EA200401077A1 (ru) | 2-оксазоламины и их применение в качестве антагонистов рецептора 5-ht2b | |
| PH12022550860A1 (en) | 5-oxa-2-azaspiro[3.4]octane derivatives as m4 agonists | |
| NO20065323L (no) | 6-substituerte pyridoindolonderivater, fremstilling og anvendelse derav | |
| EA201071259A1 (ru) | Спиро(пиперидин-4,2-пирролидин)-1-(3,5-трифторметилфенил)метилкарбоксамиды в качестве антагонистов рецептора nk1 тахикинина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |